Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer
- PMID: 36686564
- PMCID: PMC9852488
- DOI: 10.1016/j.ctro.2023.100576
Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer
Abstract
Background: The aim of this study is to quantify the short-term motion of the gastrointestinal tract (GI-tract) and its impact on dosimetric parameters in stereotactic body radiation therapy (SBRT) for pancreatic cancer.
Methods: The analyzed patients were eleven pancreatic cancer patients treated with SBRT or proton beam therapy. To ensure a fair analysis, the simulation SBRT plan was generated on the planning CT in all patients with the dose prescription of 40 Gy in 5 fractions. The GI-tract motion (stomach, duodenum, small and large intestine) was evaluated using three CT images scanned at spontaneous expiration. After fiducial-based rigid image registration, the contours in each CT image were generated and transferred to the planning CT, then the organ motion was evaluated. Planning at risk volumes (PRV) of each GI-tract were generated by adding 5 mm margins, and the volume receiving at least 33 Gy (V33) < 0.5 cm3 was evaluated as the dose constraint.
Results: The median interval between the first and last CT scans was 736 s (interquartile range, IQR:624-986). To compensate for the GI-tract motion based on the planning CT, the necessary median margin was 8.0 mm (IQR: 8.0-10.0) for the duodenum and 14.0 mm (12.0-16.0) for the small intestine. Compared to the planned V33 with the worst case, the median V33 in the PRV of the duodenum significantly increased from 0.20 cm3 (IQR: 0.02-0.26) to 0.33 cm3 (0.10-0.59) at Wilcoxon signed-rank test (p = 0.031).
Conclusion: The short-term motions of the GI-tract lead to high dose differences.
Keywords: 4DCT, four-dimensional computed tomography,; CTV, clinical target volume; FFF, flattening filter-free; GI-tract, gastrointestinal tract; GTV, gross tumor volume; Gastrointestinal tract; IQR, interquartile range; Intra-fractional motion; MV, mega-voltage; PRV, planning at risk volume; PTV, planning target volume; Pancreatic cancer; ROI, region of interest; SBRT; SBRT, stereotactic body radiation therapy; SD, standard deviation; Short-term organ motion; VMAT, volumetric modulated arc therapy.
© 2023 The Authors.
Conflict of interest statement
K.K. is an employee of the research institute of Hitachi, Ltd., currently working at Hokkaido University, under a secondary agreement. K.K. declares that this research has no relationship with Hitachi, Ltd. All other authors declare that they have no conflicts of interest.
Figures



References
-
- Chuong M.D., Springett G.M., Freilich J.M., Park C.K., Weber J.M., Mellon E.A., et al. Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated. International Journal of Radiation Oncology*Biology*Physics. 2013;86(3):516–522. - PubMed
-
- de Geus S.W.L., Eskander M.F., Kasumova G.G., Ng S.C., Kent T.S., Mancias J.D., et al. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer. 2017;123(21):4158–4167. - PubMed
-
- Herman J.M., Chang D.T., Goodman K.A., Dholakia A.S., Raman S.P., Hacker‐Prietz A., et al. Phase 2 Multi-institutional Trial Evaluating Gemcitabine and Stereotactic Body Radiotherapy for Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma. Cancer. 2015;121(7):1128–1137. - PMC - PubMed
-
- Hoyer M., Roed H., Sengelov L., Traberg A., Ohlhuis L., Pedersen J., et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76(1):48–53. - PubMed
-
- Jiang W., Haque W., Verma V., Butler E.B., Teh B.S. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. Acta Oncol. 2019;58(9):1259–1266. - PubMed
LinkOut - more resources
Full Text Sources